HER2+ Breast Cancer: Anthracycline Considerations
Experts discuss anthracycline use in HER2+ breast cancer and provide insights into how patient scenarios, heterogeneity, and neuropathy concerns shape considerations in diverse clinical situations.
EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals
EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer
EP: 3.HER2+ Breast Cancer: Anthracycline Considerations
EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends
EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring
EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer
EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer
EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials
EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer
EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases
EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights
EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges
EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer
EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
The panel discusses the use of anthracyclines in patients with HER2-positive breast cancer treatment. Rugo raises the complexity of determining whether patients need anthracyclines, particularly in cases where there’s extensive residual disease after TCHP (docetaxel, carboplatin, trastuzumab, pertuzumab) therapy. O’Shaughnessy highlights the challenge of managing tumors with heterogeneity and true biphenotypic cancers, emphasizing the importance of accurate HER2 testing and considering a preoperative AC (doxorubicin, cyclophosphamide) regimen in certain scenarios. Sharma notes situations where AC might be considered, such as when the patient has baseline peripheral neuropathy or if there are concerns about the patient completing 6 cycles of taxane-based therapy. Isaacs mentions cases with bilateral disease exhibiting different characteristics where anthracyclines may provide broader coverage. The discussion emphasizes personalized approaches, taking into account individual patient factors and tumor characteristics to optimize the treatment of patients with HER2-positive breast cancer.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
